READINESS DOSSIER
We get life sciences companies ready for diligence.
Swiss life-sciences advisory, Geneva. We run the diligence on you before your next investor does.
PATTERN 01
Investors rarely say no. They say "not yet".
PATTERN 02
"Not yet" costs you runway.
REMEDY
Start with our diligence.
THE REFRAME
Investors don't buy your science. They price your risk.
Every question in diligence is the same question: what could go wrong, and do you know it before they do?
METHOD
Every investor runs diligence. Ours comes first.
01
Map
The diligence your next investor will run, at the bar of that round.
02
Fix
What breaks gets fixed, in the order that moves valuation.
03
Prove
A data room that answers before they ask.
HOW WE WORK
Five steps. We stay for all of them.
- 01 Map Our diligence first: the route, then what breaks.
- 02 Structure Entity, governance, IP, cap table.
- 03 Fix Science reviewed. Trials, model, plan fixed.
- 04 Prove Evidence in the data room, before they ask.
- 05 Govern Board seat, or the seat behind it.
SERVICES
Six services, one entry point
THE ENTRY POINT
Readiness diligence
What will the next investor find, and what has to change first?
You receive: Assessment, ranked gaps, remediation plan
Scope and deliverablesData room
Can every diligence request be answered from a document?
Market and competitive analysis
How large is the opportunity, and who else is going after it?
Fractional CFO
Is the money buying milestones?
Fractional CMO
Is your programme ready for the clinic, and is the plan aligned with milestones, investors and regulators?
Board support
Does the board have what it needs to decide?
WHO WE ARE
We have sat where your investors sit.
THE PHYSICIAN SCIENTIST
Patricia Delaite, MD
Oncologist. Twice a biotech CMO. Trials supporting Series A to C and an exit. Board experience: listed companies and start-ups.
in
THE BANKER
Jean-Marc Suter
Swiss banker in Geneva, London and Abu Dhabi. Thirty years of pitches across his desk. He knows where they break.
inWorking in English and French, from Geneva.
YOUR DOSSIER: NOT YET WRITTEN
Start with our diligence, before your next investor runs theirs.